FCCC LOGO Faculty Publications
Botejue M , Abbott D , Danella J , Fonshell C , Ginzburg S , Guzzo TJ , Lanchoney T , Marlowe B , Raman JD , Smaldone M , Tomaszewski JJ , Trabulsi EJ , Uzzo RG , Reese AC
Active Surveillance as Initial Management of Newly Diagnosed Prostate Cancer: Data from the PURC
J Urol. 2019 May;201(5) :929-936
Back to previous list
PURPOSE: We describe contemporary active surveillance utilization and variation in a regional prostate cancer collaborative. We identified demographic and disease specific factors associated with active surveillance in men with newly diagnosed prostate cancer. MATERIALS AND METHODS: We analyzed data from the PURC (Pennsylvania Urologic Regional Collaborative), a cooperative effort of urology practices in southeastern Pennsylvania and New Jersey. We determined the rates of active surveillance among men with newly diagnosed NCCN(R) (National Comprehensive Cancer Network(R)) very low, low or intermediate prostate cancer and compared the rates among participating practices and providers. Univariate and multivariable analyses were used to identify factors associated with active surveillance utilization. RESULTS: A total of 1,880 men met inclusion criteria. Of the men with NCCN very low or low risk prostate cancer 57.4% underwent active surveillance as the initial management strategy. Increasing age was significantly associated with active surveillance (p <0.001) while adverse clinicopathological variables were associated with decreased active surveillance use. Substantial variation in active surveillance utilization was observed among practices and providers. CONCLUSIONS: More than 50% of men with low risk disease in the PURC collaborative were treated with active surveillance. However, substantial variation in active surveillance rates were observed among practices and providers in academic and community settings. Advanced age and favorable clinicopathological factors were strongly associated with active surveillance. Analysis of regional collaboratives such as the PURC may allow for the development of strategies to better standardize treatment in men with prostate cancer and offer active surveillance in a more uniform and systematic fashion.
Botejue, Mahesh Abbott, Daniel Danella, John Fonshell, Claudette Ginzburg, Serge Guzzo, Thomas J Lanchoney, Thomas Marlowe, Bret Raman, Jay D Smaldone, Marc Tomaszewski, Jeffrey J Trabulsi, Edouard J Uzzo, Robert G Reese, Adam C eng J Urol. 2019 May;201(5):929-936. doi: 10.1016/j.juro.2018.10.018.